StockData
Royalty Pharma plc logo

Royalty Pharma plc (RPRX) stock

RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3050% above fair value
$68.67−0.01 (-0.01%)

Close on Nov 18, 2026Market cap $39.49BP/E 39.0Yield –

Royalty Pharma revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Royalty Pharma's revenue for the twelve months ending Jun 30, 2026 was $2.54B, up 10.0% year over year. For fiscal 2025 it was $2.38B, up 5.1% from the year before. The highest annual figure on record is $2.38B in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.38B+5.1%
FY2024Dec 31, 2024$2.26B-3.9%
FY2023Dec 31, 2023$2.35B+5.2%
FY2022Dec 31, 2022$2.24B-2.3%
FY2021Dec 31, 2021$2.29B+7.9%
FY2020Dec 31, 2020$2.12B+17.0%
FY2019Dec 31, 2019$1.81B+1.1%
FY2018Dec 31, 2018$1.79B–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$674.14M+16.5%
Q1 FY2026Mar 31, 2026$630.58M+11.0%
Q4 FY2025Dec 31, 2025$621.99M+4.8%
Q3 FY2025Sep 30, 2025$609.29M+7.9%
Q2 FY2025Jun 30, 2025$578.67M+7.7%
Q1 FY2025Mar 31, 2025$568.25M+0.0%
Q4 FY2024Dec 31, 2024$593.64M-0.4%
Q3 FY2024Sep 30, 2024$564.69M+5.3%
Q2 FY2024Jun 30, 2024$537.27M-0.2%
Q1 FY2024Mar 31, 2024$567.98M-17.0%
Q4 FY2023Dec 31, 2023$596.07M+5.4%
Q3 FY2023Sep 30, 2023$536.31M-6.5%
Q2 FY2023Jun 30, 2023$538.20M+0.4%
Q1 FY2023Mar 31, 2023$683.97M+21.7%
Q4 FY2022Dec 31, 2022$565.75M-1.7%
Q3 FY2022Sep 30, 2022$573.46M-2.1%
Q2 FY2022Jun 30, 2022$535.96M-3.4%
Q1 FY2022Mar 31, 2022$562.05M-1.9%
Q4 FY2021Dec 31, 2021$575.70M+0.6%
Q3 FY2021Sep 30, 2021$585.77M+8.8%
Q2 FY2021Jun 30, 2021$554.96M+8.6%
Q1 FY2021Mar 31, 2021$573.03M+14.4%
Q4 FY2020Dec 31, 2020$572.14M+25.1%
Q3 FY2020Sep 30, 2020$538.40M+16.0%
Q2 FY2020Jun 30, 2020$510.93M+11.7%
Q1 FY2020Mar 31, 2020$500.88M–
Q4 FY2019Dec 31, 2019$457.49M–
Q3 FY2019Sep 30, 2019$464.28M–
Q2 FY2019Jun 30, 2019$457.61M–

More Royalty Pharma figures

See a number that looks wrong?